

Vetenskaplig produktion helt eller delvis baserad på data från registret publicerat under 2023:

1. Krali, O., Marincevic-Zuniga, Y., Arvidsson, G., Enblad, A. P., Lundmark, A., Sayyab, S., Zachariadis, V., Heinäniemi, M., Suhonen, J., Oksa, L., Vepsäläinen, K., Öfverholm, I., Barbany, G., Nordgren, A., Lilljebjörn, H., Fioretos, T., Madsen, H. O., Marquart, H. V., Flaegstad, T., ... Nordlund, J. (2023). Multimodal classification of molecular subtypes in pediatric acute lymphoblastic leukemia. *NPJ Precision Oncology*, 7(1), 131–131. <https://doi.org/10.1038/s41698-023-00479-5>
2. Lynggaard, L. S., Lynggaard, L. S., Rank, C. U., Als-Nielsen, B., Hoejfeldt, S. G., Heyman, M., Schmiegelow, K., and Albertsen, B. K. (2023). PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysis. *Cochrane Database of Systematic Reviews*, 2023(5), CD014570–CD014570. <https://doi.org/10.1002/14651858.CD014570.pub2>
3. Kampitsi, C.-E., Nordgren, A., Mogensen, H., Pontén, E., Feychting, M., and Tettamanti, G. (2023). Neurocutaneous Syndromes, Perinatal Factors, and the Risk of Childhood Cancer in Sweden. *JAMA Network Open*, 6(7), e2325482–e2325482. <https://doi.org/10.1001/jamanetworkopen.2023.25482>
4. Grundström, A., Harila, A., and Lönnerblad, M. (2024). Educational and occupational outcomes in Swedish children treated for sarcomas: A nationwide registry-based study. *Pediatric Blood & Cancer*, 71(1), e30719–e30719. <https://doi.org/10.1002/pbc.30719>
5. Lönnerblad, M., Suominen, R., and Harila-Saari, A. (2023). Childhood lymphoma treatment impacts educational outcomes: a registry study from Sweden. *Journal of Cancer Survivorship*, 17(4), 1072–1081. <https://doi.org/10.1007/s11764-022-01266-0>
6. Karlsson, L., Cheuk, D., De Moerloose, B., Hasle, H., Jahnukainen, K., Juul-Dam, K. L., Kaspers, G., Kovalova, Z., Lausen, B., Nyström, U. N., Palle, J., Pronk, C. J., Saks, K., Tierens, A., Zeller, B., and Abrahamsson, J. (2023). Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia. *British Journal of Haematology*, 201(4), 757–765. <https://doi.org/10.1111/bjh.18685>
7. Öfverholm, I., Rezayee, F., Heyman, M., Harila, A., Arvidsson, L., Schmiegelow, K., Norén-Nyström, U., and Barbany, G. (2023). The prognostic impact of IKZF1 deletions and UKALL genetic classifiers in paediatric B-cell precursor acute lymphoblastic leukaemia treated according to NOPHO 2008 protocols. *British Journal of Haematology*, 202(2), 384–392. <https://doi.org/10.1111/bjh.18852>
8. Mogensen, N., Kreicbergs, U., Albertsen, B. K., Lähteenmäki, P., Heyman, M., and Harila, A. (2023). Parental experiences of the informed consent process in randomized clinical trials—A Nordic study. *Pediatric Blood & Cancer*, 70(12), e30684–e30684. <https://doi.org/10.1002/pbc.30684>
9. Egnell, C., Hallböök, H., Heyman, M., Wartiovaara-Kautto, U., Quist-Paulsen, P., Schmiegelow, K., Griskevicius, L., Palk, K., Toft, N., Overgaard, U. M., Harila, A., and Ranta, S. (2023). Impact of body mass index on outcome and treatment-related toxicity in young adults with acute lymphoblastic leukemia. *Acta Oncologica*, 62(12), 1723–1731. <https://doi.org/10.1080/0284186X.2023.2258450>
10. Egnell Gustafsson, C. (2023). Impact of body mass index on outcome, toxicity and pharmacokinetics in patients with acute lymphoblastic leukemia. *Inst för kvinnors och barns hälsa / Dept of Women's and Children's Health*.
11. Schepke, E., Löfgren, M., Pietsch, T., Kling, T., Nordborg, C., Olsson Bontell, T., Holm, S., Öberg, A., Nyman, P., Eliasson-Hofvander, M., Sabel, M., Lannering, B., and Carén, H.

- (2023). Supratentorial CNS-PNETs in children; a Swedish population-based study with molecular re-evaluation and long-term follow-up. *Clinical Epigenetics*, 15(1), 40–40. <https://doi.org/10.1186/s13148-023-01456-2>
12. Lönnerblad, M., Berglund, E., Åberg, M., and Blomgren, K. (2023). Occupational outcomes after high-grade or low-grade brain tumors in childhood: A Swedish, nationwide, registry-based study. *Cancer Medicine (Malden, MA)*, 12(6), 7459–7469. <https://doi.org/10.1002/cam4.5464>
 13. Lönnerblad, M., Åberg, M., Blomgren, K., and Berglund, E. (2023). Post-Compulsory Education in Teenagers and Young Adults Treated for Brain Tumors in Childhood: A Swedish Nationwide Registry-Based Study. *Cancers*, 15(1), 255-. <https://doi.org/10.3390/cancers15010255>
 14. Skog, R., Lampic, C., Olsson, E., and Wettergren, L. (2023). The role of a discussion forum within a web-based psychoeducational intervention focusing on sex and fertility- What do young adults communicate? *Cancer Medicine (Malden, MA)*, 12(16), 17273–17283. <https://doi.org/10.1002/cam4.6317>
 15. Haavisto, A., Wettergren, L., Lampic, C., Lähteenmäki, P. M., and Jahnukainen, K. (2023). Premature ovarian insufficiency and chance of pregnancy after childhood cancer: A population-based study (the Fex-Can study). *International Journal of Cancer*, 153(3), 644–653. <https://doi.org/10.1002/ijc.34541>
 16. Bergström, C., Lampic, C., Roy, R., Hedman, C., Ahlgren, J., Ståhl, O., Smedby, K. E., Hellman, K., Henriksson, R., Eriksson, L. E., and Wettergren, L. (2023). Do young adults with cancer receive information about treatment-related impact on sex life? Results from a population-based study. *Cancer Medicine (Malden, MA)*, 12(8), 9893–9901. <https://doi.org/10.1002/cam4.5672>
 17. Rodriguez-Wallberg, K. A., Ahlgren, J., Smedby, K. E., Gorman, J. R., Hellman, K., Henriksson, R., Ståhl, O., Wettergren, L., and Lampic, C. (2023). Prevalence and predictors for fertility-related distress among 1010 young adults 1.5 years following cancer diagnosis – results from the population-based Fex-Can Cohort study. *Acta Oncologica*, 62(12), 1599–1606. <https://doi.org/10.1080/0284186X.2023.2272291>
 18. De Moerloose, B., Arad-Cohen, N., Cheuk, D., Fernandez Navarro, J. M., Hasle, H., Jahnukainen, K., Kaspers, G. J. L., Kovalova, Z., Lausen, B., Norén-Nyström, U., Palle, J., Pasauliene, R., Pronk, C. J., Saks, K., Tierens, A. M., Zeller, B., and Abrahamsson, J. (2023). A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol. *Blood*, 142(Supplement 1), 831–831. <https://doi.org/10.1182/blood-2023-187251>
 19. Zeller, B., Arad-Cohen, N., Cheuk, D., De Moerloose, B., Fernandez Navarro, J. M., Hasle, H., Kirsi, J., Juul-Dam, K., Kaspers, G. J. L., Kovalova, Z., Lausen, B., Munthe-Kaas, M. C., Norén-Nyström, U., Palle, J., Pasauliene, R., Pronk, C. J., Saks, K., Tierens, A. M., and Abrahamsson, J. (2023). Management of Hyperleukocytosis in Pediatric Acute Myeloid Leukemia Using Immediate Chemotherapy without Leukapheresis, in Protocol NOPHO-DBH AML-2012. *Blood*, 142(Supplement 1), 2852–2852. <https://doi.org/10.1182/blood-2023-184921>
 20. Norén-Nyström, U., Andersen, M. K., Barbany, G., Dirse, V., Eilert-Olsen, M., Engvall, M., Harila-Saari, A., Heyman, M., Hovland, R., Häikiö, S., Jónsson, J. J., Karhu, R., Kjeldsen, E., Norberg, A., Preiss, B. S., Pulkkinen, K., Quist-Paulsen, P., Räsänen, H., Schmiegelow, K., ... Johansson, B. (2023). Genetic Subtypes and Outcome of Patients

- Aged 1 to 45 Years Old With Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Trial. *HemaSphere*, 7(5), e883-n/a. <https://doi.org/10.1097/HS9.0000000000000883>
21. Thiblin, E., Woodford, J., Reuther, C., Lundgren, J., Lutvica, N., and Essen, L. (2023). Internet-administered, low-intensity cognitive behavioral therapy for parents of children treated for cancer: A feasibility trial (ENGAGE). *Cancer Medicine (Malden, MA)*, 12(5), 6225–6243. <https://doi.org/10.1002/cam4.5377>